Back

P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting

European Heart Journal - Cardiovascular Pharmacotherapy

8 August 2023
Organised by: Logo
Read full article
ESC Journals

Contributors

Kyriakos Dimitriadis
Kyriakos Dimitriadis

Author

Hippokration General Hospital Athens , Greece

Nikolaos Pyrpyris
Nikolaos Pyrpyris

Author

Konstantinos Aznaouridis
Konstantinos Aznaouridis

Author

Konstantinos Tsioufis
Konstantinos Tsioufis

Author

You may be interested in
thumbnail
Congress Presentation
Ticagrelor or prasugrel in patients with acute coronary syndrome and high bleeding risk
27 August 2022
thumbnail
Webinar
Balancing stroke and bleeding risks in patients with AF and concomitant coronary artery disease, malignancy, chronic kidney disease, or frailty
10 November 2025
thumbnail
Congress Presentation
P2Y12 inhibitor monotherapy in patients undergoing PCI.
26 August 2022
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
6 July 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources